Proof of principle is provided for drug-controllable KCNA1 gene therapy as a promising treatment avenue for epilepsy related to SCN2A LoF variants by normalized elevated neuronal firing and reduced spontaneous seizure burden in Scn2a-deficient mice.
Zai-Yang Zhang, Jing-Liang Zhang, Xiao-Ling Chen et al.· Journal of Clinical Investig...· 0 citations
Overall, the successful use of an inducible AAV-mediated gene delivery system to supplement hKv1.1 expression to mitigate neuronal hyperexcitability and ameliorate social impairments in a mouse model of SCN2A-related ASD is demonstrated.
Brody A. Deming, Jing-Liang Zhang, Iuliia Vitko et al.· bioRxiv· 1 citation
These findings demonstrate that the Nav1.2-L1342P mutation drives a multifaceted disease phenotype, including network hyperexcitability and disruption of pathways related to neuronal and synaptic functions, which advances understanding of SCN2A-related developmental and epileptic encephalopathy (DEE).
M. I. Olivero-Acosta, Morgan Robinson, Zhefu Que et al.· Epilepsia· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.